JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265197

Human PHLDA3 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PHLDA3 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

View Alternative Names

PHLA3_HUMAN, Pleckstrin homology like domain family A member 2, Pleckstrin homology-like domain family A member 3, TDAG51/Ipl homolog 1, TDAG51/Ipl homologue 1, TIH 1

1 Images
Sanger Sequencing - Human PHLDA3 knockout HeLa cell line (AB265197)
  • Sanger seq

Unknown

Sanger Sequencing - Human PHLDA3 knockout HeLa cell line (AB265197)

Homozygous : 1 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265197-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265197 Human PHLDA3 knockout HeLa cell line", "number":"AB265197-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265197-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265197 Human PHLDA3 knockout HeLa cell line", "number":"AB265197-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PHLDA3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PHLDA3 also known as PHLDA family member 3 is a small protein with a molecular mass of about 15 kDa. It functions mechanically as an antagonist of the AKT signaling pathway. PHLDA3 can inhibit AKT by binding to its pleckstrin homology (PH) domain preventing AKT's interaction with other molecules. This protein is expressed in various tissues throughout the body including the brain lungs and liver indicating its role in diverse cellular functions.
Biological function summary

The protein acts as a tumor suppressor through its ability to regulate cell growth and apoptosis. PHLDA3 does this by modulating the AKT pathway inhibiting cell survival and promoting apoptosis. It is not part of a larger complex but interacts directly with other proteins to execute its function. The influence of PHLDA3 on cell cycle processes suggests it plays roles in maintaining normal cellular functions and preventing uncontrolled proliferation.

Pathways

Several studies have shown PHLDA3 integrates into the p53 signaling pathway a critical pathway for cellular stress responses and tumor suppression. It interacts with the AKT pathway which connects it to proteins like PI3K and PTEN influencing cellular growth and apoptosis. PHLDA3 effectively bridges interaction between the p53 pathway and AKT pathway which balances cell fate decisions under stress conditions.

PHLDA3 exhibits a significant impact on cancer development and progression. Loss of PHLDA3 expression has been observed in various tumors suggesting its role in cancer development. Additionally it relates to diabetes where altered AKT signaling affects insulin response. In cancer PHLDA3 connects to the tumor suppressor protein p53 influencing its regulatory functions while in diabetes its relation to AKT pathway points to disturbances in glucose homeostasis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com